We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node-Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer
- Authors
Guiyun Sohn; Sei Hyun Ahn; Hee Jeong Kim; Byung-Ho Son; Jong Won Lee; Beom Seok Ko; Yura Lee; Sae Byul Lee; Seunghee Baek
- Abstract
Purpose: The purpose of this study was to compare treatment outcomes between combined gonadotropin-releasing hormone agonist and tamoxifen (GnRHa+T) and sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen (AC->T) in premenopausal patients with hormone-responsive, lymph-node-negative breast cancer. Materials and Methods: In total, 994 premenopausal women with T1-T2, lymph-node-negative, hormone-receptorpositive, HER2-negative breast cancer between January 2003 and December 2008 were included in this retrospective cohort study. GnRHa+T and AC->T were administered to 608 patients (61.2%) and 386 patients (38.8%), respectively. Propensity score matching and inverse probability weighting were applied to the original cohort, and 260 patients for each treatment arm were included in the final analysis. Recurrence-free, cancer-specific, and overall survival was compared between the two treatment groups. Results: A total of 994 patients were followed up for a median of 7.4 years (range, 0.5 to 11.4 years). The 5-year follow-up rate was 98.7%, and 13 patients were lost to follow-up. In propensitymatched cohorts (n=520), there was no difference in recurrence-free, cancer-specific, and overall survival rates between the two treatment groups (p=0.306, p=0.212, and p=0.102, respectively), and this was maintained after applying inverse probability weighting. Conclusion: GnRHa+T is a reasonable alternative to AC-> T in patients with premenopausal, hormoneresponsive, HER2-negative, lymph-node-negative, T1-T2 breast cancer.
- Subjects
BREAST cancer chemotherapy; LUTEINIZING hormone releasing hormone agonists; TAMOXIFEN; DOXORUBICIN; CYCLOPHOSPHAMIDE; HER2 gene; LYMPH nodes; PERIMENOPAUSE; THERAPEUTICS
- Publication
Cancer Research & Treatment, 2016, Vol 48, Issue 4, p1351
- ISSN
1598-2998
- Publication type
Article
- DOI
10.4143/crt.2015.444